Merck & Co (NY:MRK)

Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

November 13, 2026

Performance

52-Week Range 5.8% below 52-week high

147.76

90.9052W Low 156.9252W High

1 Week 1.0% below 1-week high

145.241W Low 149.311W High

Merck & Co (MRK) traded between $90.90 and $156.92 over the past 52 weeks and last traded at $147.76, 5.8% below its 52-week high. Over the past week it ranged between $145.24 and $149.31.

Past 12 Months

-0.7%

+0.3%

+8.8%

+32.7%

+38.8%

+59.0%

1W -$1.00

1M +$0.39

3M +$11.92

6M +$36.38

YTD +$41.31

1Y +$54.83

MRK was +59.0% over the past year, +32.7% over six months, +38.8% year to date, -0.7% in the last week.

12 Months vs Market

MRK

+59.0%

DIA

+10.2%

SPY

+12.3%

QQQ

+11.8%

IWM

+17.2%

Over the past 12 months MRK returned +59.0% versus DIA (Dow) +10.2%, SPY (S&P 500) +12.3%, QQQ (Nasdaq 100) +11.8% and IWM (Russell 2000) +17.2%.

Volume & Liquidity 0.64× 3-mo avg

Today 6,507,627 3-mo avg 10.2M

6.5M

9.9M

10.2M

10.3M

YTD

10.6M

11.2M

MRK most recently traded 6,507,627 shares against a 3-month average daily volume of 10.2M.

More News

3 Pharmaceutical Stocks That Offer Safety and Growth ↗

November 12, 2026

Dow Jones Losers on Nov. 3, 2026: SHW, HD and MRK Lead Declines ↗

November 03, 2026

Via Chartmill

Dow Jones Biggest Decliners in Today's US Session ↗

November 03, 2026

Via Chartmill

Merck to Participate in the Jefferies Global Healthcare Conference in London

November 12, 2026

The AI Debt Bill Is Coming Due, But Biotech Has Revenue to Show for the Boom ↗

November 11, 2026

Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

November 09, 2026

Moderna Just Gave Investors Yet Another Thing to Cheer About ↗

November 06, 2026

2 Growth Stocks to Buy in November Without Any Hesitation ↗

November 05, 2026

History Says This ETF Is a Fantastic Buy-and-Hold Investment -- and It Could Turn $100 per Month Into $359,492 ↗

November 04, 2026

Moderna's Cancer Vaccine Is Incredibly Promising, but This Could Be a Major Obstacle to Its Success ↗

November 03, 2026

3 Stocks That Did Well the Last Time the Fed Raised Rates Aggressively ↗

November 03, 2026

Tempus AI Surges on Earnings Beat, But Can the Rally Last? ↗

November 03, 2026

Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

November 03, 2026

Here's Why I Think Every Investor Needs to Invest in These "Miracle" Drugs ↗

November 02, 2026

Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

November 02, 2026

Why Merck Stock Flew Higher on Friday ↗

October 30, 2026

Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop

MRK Q3 deep dive: oncology launches, clinical pipeline advances, and margin headwinds

October 30, 2026

Via StockStory

October 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 1.76% Share Price Decline

October 30, 2026

From The Law Offices of Howard G. Smith

Merck & Co., Inc. Q3 Earnings Call Highlights ↗

October 30, 2026

Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R. Cruz Investigates Potential Securities Fraud After 1.76% Stock Decline

October 29, 2026

From The Law Offices of Frank R. Cruz

Dow Jones Top Movers for Oct. 29, 2026: Merck and Nike Lead Gainers, Alphabet and Caterpillar Fall ↗

October 29, 2026

Via Chartmill

Merck (MRK) Q3 2026 Earnings Call Transcript ↗

October 29, 2026